Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Mattison

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Cytotherapy|February 20, 2022
Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): Study protocol for a phase 1 dose-escalation trial of patients with xerostomia after radiation therapy for head and neck cancer: MARSH: Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary HypofunctionGrace C Blitzer, Nicole M Rogus-Pulia, Ryan J Mattison, et al.
Cytotherapy|August 17, 2023
Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): A pilot, first-in-human study of interferon gamma-stimulated marrow mesenchymal stromal cells for treatment of radiation-induced xerostomiaGrace C Blitzer, Tiffany Glazer, Adam Burr, et al.
Investigational New Drugs|December 9, 2014
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasiaOlatoyosi Odenike, Anna Halpern, Lucy A Godley, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2024
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network StudyJulie E Chang, Danielle McQuinn, Meredith Hyun, et al.
Radiology|October 4, 2022
Multicenter Reproducibility of Liver Iron Quantification with 1.5-T and 3.0-T MRIDiego Hernando, Ruiyang Zhao, Qing Yuan, et al.
Leukemia & Lymphoma|June 5, 2024
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trialVikas Gupta, Abdulraheem Yacoub, Ruben A Mesa, et al.
Journal of Magnetic Resonance Imaging : JMRI|April 25, 2024
Practical Application of Multivendor MRI-Based R2* Mapping for Liver Iron Quantification at 1.5 T and 3.0 TGregory Simchick, Ruiyang Zhao, Qing Yuan, et al.
Blood Advances|September 7, 2021
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALLMatthew J Wieduwilt, Jun Yin, Meir Wetzler, et al.
Magnetic Resonance in Medicine|September 6, 2024
Multicenter, multivendor validation of liver quantitative susceptibility mapping in patients with iron overload at 1.5 T and 3 TCollin J Buelo, Julia Velikina, Lu Mao, et al.
Cancer|June 17, 2015
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network studyTimothy S Fenske, Namrata M Shah, Kyung Mann Kim, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Cytotherapy|February 20, 2022
Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): Study protocol for a phase 1 dose-escalation trial of patients with xerostomia after radiation therapy for head and neck cancer: MARSH: Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary HypofunctionGrace C Blitzer, Nicole M Rogus-Pulia, Ryan J Mattison, et al.
Cytotherapy|August 17, 2023
Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): A pilot, first-in-human study of interferon gamma-stimulated marrow mesenchymal stromal cells for treatment of radiation-induced xerostomiaGrace C Blitzer, Tiffany Glazer, Adam Burr, et al.
Investigational New Drugs|December 9, 2014
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasiaOlatoyosi Odenike, Anna Halpern, Lucy A Godley, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2024
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network StudyJulie E Chang, Danielle McQuinn, Meredith Hyun, et al.
Radiology|October 4, 2022
Multicenter Reproducibility of Liver Iron Quantification with 1.5-T and 3.0-T MRIDiego Hernando, Ruiyang Zhao, Qing Yuan, et al.
Leukemia & Lymphoma|June 5, 2024
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trialVikas Gupta, Abdulraheem Yacoub, Ruben A Mesa, et al.
Journal of Magnetic Resonance Imaging : JMRI|April 25, 2024
Practical Application of Multivendor MRI-Based R2* Mapping for Liver Iron Quantification at 1.5 T and 3.0 TGregory Simchick, Ruiyang Zhao, Qing Yuan, et al.
Blood Advances|September 7, 2021
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALLMatthew J Wieduwilt, Jun Yin, Meir Wetzler, et al.
Magnetic Resonance in Medicine|September 6, 2024
Multicenter, multivendor validation of liver quantitative susceptibility mapping in patients with iron overload at 1.5 T and 3 TCollin J Buelo, Julia Velikina, Lu Mao, et al.
Cancer|June 17, 2015
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network studyTimothy S Fenske, Namrata M Shah, Kyung Mann Kim, et al.
Pageof 4